Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings Africa-Europe partnership launches study to evaluate emergency response tools for severe malaria in highly isolated rural settings. 27 November 2023
First African-manufactured combination therapy for seasonal malaria chemoprevention receives WHO prequalification 6 November 2023 Universal Corporation Ltd (UCL), a Strides Pharma Science Limited (Strides) enterprise, with support from MMV, has become the first African manufacturer to gain WHO prequalification for their sulfadoxine-pyrimethamine + amodiaquine product.
Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria 21 August 2023
Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria 6 June 2023
Medicines for Malaria Venture and the Africa CDC sign Memorandum of Understanding to support African manufacturers 15 December 2022
Strong recommendation for pyronaridine-artesunate in revised WHO Malaria Treatment Guidelines 25 November 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Photo: Bill Wegener on Unsplash 23 November 2022
First African-manufactured medicine to prevent malaria in pregnant women and infants quality-approved by WHO Universal Corporation Ltd (UCL), with support from MMV and Unitaid, becomes the first African manufacturer to gain WHO prequalification of sulfadoxine-pyrimethamine 25 August 2022
MMV and IVCC make 240 compounds available to stimulate research into new drugs and insecticides Diverse compound collection harnesses open innovation to advance global health priorities 13 August 2022
Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration Novel paediatric relapse-prevention treatment marks a major contribution towards malaria elimination efforts. 14 March 2022
Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria 29 September 2021
New partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide Partnership to support endemic countries in achieving their Plasmodium vivax (P. vivax) malaria elimination goals. 14 July 2021
Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa Study run in partnership with the CANTAM network and published in PLoS Medicine supports further uptake of antimalarial in Africa. 17 June 2021
This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria MMV echoes Swiss Malaria Group's recognition of progress made despite challenges posed by COVID-19, and supports the call for sustained commitment. 19 April 2021
New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010 PDPs reduce investment risks and stretch limited budgets leading to 375 innovations targeting infectious diseases under development. 28 January 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration Acceptance to review the paediatric dossier by the Australian drug regulator is an important and big step towards making this medicine available to the children that need it 8 January 2021
MMV supports the launch of the new Fight the Fakes Alliance This Fight the Fakes week, MMV becomes part of a newly formed alliance with the crucial mission of combatting falsified medicines. 7 December 2020
Global call to boost access to lifesaving malaria treatment for pregnant women in Africa 15 October 2020
MMV launches the COVID Box to stimulate new drug research Box contains a standard set of compounds with known or predicted activity against SARS-CoV2 10 June 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria 24 April 2020